Background Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a
recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (…

Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …

Objectives A number of vaccines have now been developed against COVID-19. Differences
in reactogenicity and safety profiles according to the vaccine technologies employed are …

Background The recombinant protein-based vaccine, NVX-CoV2373, demonstrated 89.7%
efficacy against coronavirus disease 2019 (COVID-19) in a phase 3, randomized, observer-…

Background The omicron BA.1 bivalent booster is used globally. Previous open-label studies
of the omicron BA.1 (Moderna mRNA-1273.214) booster showed superior neutralising …

Background Priming COVID-19 vaccine schedules have been deployed at variable intervals
globally, which might influence immune persistence and the relative importance of third-…

Background Covid-19 vaccines are urgently needed, especially against emerging variants.
NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (SARS-…

Introduction Different COVID-19 vaccines are being utilized as boosters. This systematic
review and meta-analysis aims to evaluate the reactogenicity of COVID-19 vaccines given as …

Background Omicron-containing bivalent boosters are available worldwide. Results of a
large, randomized, active-controlled study are presented. Methods This phase 3, randomized, …

Introduction: Different COVID-19 vaccines are being utilized as boosters. This systematic
review and meta-analysis aims to evaluate the reactogenicity of COVID-19 vaccines given as …